2010•Unpublished venueRequires access
Bosentan Pediatric Patients with Pulmonary Arterial Hypertension
Natalie J. Carter, Gillian M. Keating
Open publisher page 1 citations
Abstract
Bosentan is a dual endothelin-1 (ET-1) receptor antagonist that has affinity for ET-1 receptors A and B. In the EU, oral bosentan (Tracleer � ) is indicated to improve exercise capacity and symptoms in patients with pulmonary arterial hypertension (PAH) of WHO functional class III; benefits have also been seen in patients with WHO functional class II PAH. Bosentan is available as film-coated tablets, and a new dispersible formulation of bosentan has also recently been approved in the EU for the treatment of PAH in children aged ‡2 years. A noncomparative, multicenter, phase III trial (FUTURE-1), which was primarily designed to investigate the pharmacokinetics of dispersible bosentan in pediatric patients, demonstrated that increasing the dosage of bosentan from 2 to 4 mg/kg twice daily was